Podcasts about Policy

What does it take to lead through one of the most defining battles in CRNA history? In this Courage to Lead conversation, Larry Hornsby, CRNA, BSN reflects on his presidency during a pivotal and tumultuous era for the AANA at the turn of the century. Facing national policy shifts, physician supervision debates, and an all-out fight with the ASA, Larry shares the behind-the-scenes stories of late-night strategy sessions, fax campaigns to Congress, and standing on the rope line with President Clinton. This episode is more than history—it's a powerful look at leadership under pressure, the sacrifices required, and the resilience that shaped the future of nurse anesthesia. Here's some of what you'll hear in this episode: ⚖️ Policy at the crossroads – How supervision became the central fight for CRNAs.

A woman walking on a South Carolina sidewalk is killed by a man who admits he'd been drinking since 6 a.m. — and the conversation immediately turns to policy. In this episode we use that tragic case to interrogate state choices that, critics say, let dangerous people stay on the road: why governors won't deputize every officer, how deputization works, and whether political and economic interests trump public safety. Expect a hard‑edged breakdown of the facts, the laws (287(g) vs. full deputization), and the promises candidates have made — plus a blunt demand for accountability from elected leaders.

COVID has caused more than 7 million confirmed deaths (and estimates of the actual total go well past 20 million). Here’s the even worse news: It wasn’t the truly devastating pandemic epidemiologists have feared for decades. But here’s the good news: We learned every possible lesson from COVID, and now we’re utterly prepared for the next big pandemic that’s inevitably barreling towards us. No. Wait. Maybe I’ve gotten that last bit wrong. This hour, Michael Osterholm, founding director of the Center for Infectious Disease Research and Policy, joins us to talk about the dreaded potential “big one” and what we need to do to be ready. GUEST: Michael T. Osterholm: Founding director of the Center for Infectious Disease Research and Policy at the University of Minnesota and the co-author of The Big One: How We Must Prepare for Future Deadly Pandemics The Colin McEnroe Show is available as a podcast on Apple Podcasts, Spotify, Amazon Music, TuneIn, Listen Notes, or wherever you get your podcasts. Subscribe and never miss an episode! Subscribe to The Noseletter, an email compendium of merriment, secrets, and ancient wisdom brought to you by The Colin McEnroe Show. Join the conversation on Facebook and Twitter. Colin McEnroe contributed to this show.Support the show: http://www.wnpr.org/donateSee omnystudio.com/listener for privacy information.

Send us a textJayne Amelia speaks with Dr. Lucretia “Cre” Taylor,  a seasoned strategist and consultant with over two decades of experience leading and supporting organizations across the nonprofit and public sectors. Her expertise spans strategic planning, program design, evaluation, organizational development, and capacity building—particularly for organizations advancing equity, healing, and access for historically marginalized communities. Dr. Cre is the founder of Strategic Choices Consulting, where she works closely with nonprofits, funders, and coalitions to strengthen infrastructure, align programs with outcomes, and move from vision to impact.While deeply committed to youth-serving organizations, Dr. Cre's portfolio includes a wide range of mission areas—from education and mental health to justice reform, housing, and leadership development. Her consulting work focuses on helping organizations sharpen their strategy, build sustainable programs, design meaningful partnerships, and increase their readiness for funding and growth. She has supported over 200 organizations nationwide through technical assistance, training, and implementation support—facilitating organizational assessments, strategic planning retreats, program audits, and leadership coaching.A former foster youth turned scholar-practitioner, Dr. Cre draws on both personal experience and research expertise to inform her work. She holds a Ph.D. in Education with an emphasis in Policy, Reform, and Evaluation from Claremont Graduate University, a Master's degree in Urban Affairs & Public Policy with an emphasis in Nonprofit Management and Evaluation from the University of Delaware, and a Bachelor's degree from Spelman College. Dr. Cre was recognized as an “American Champion” by PBS for her contributions to education and community transformation.She is also a sought-after speaker and facilitator known for her engaging, affirming approach to leading conversations on systems change, trauma-informed practice, and community-led design. Whether helping organizations develop a strategic roadmap, align programs with community needs, or build internal capacity, Dr. Cre brings thought partnership, clarity, and care to every engagement.See bonusbabies.org to learn more about what we are doing and please donate to support us by making a 100% tax-deductible contribution. EVERY PENNY OF YOUR CONTRIBUTION GOES TO RECORDING AND PLATFORMING THESE STORIES. Yeah!IG@bonusbabiespodcastTW@BonusBabiesPodFB@BonusBabiesPodcast

French politicians have been doing politics. This week's prime minister, Lecornu, has suggested that a majority of national assembly members favor seeking a compromise budget. The suggestion is less fiscal tightening than was originally proposed. French assets are likely to continue to command a risk premium, but the bond market should remain orderly.

What if our approach to vaccines—one of the greatest medical achievements in history—has lost sight of its most important principle: trust?In this week's Let People Prosper Show, I talk with Dr. Monique Yohanan, a physician, policy leader, and innovator who's spent more than 20 years at the crossroads of medicine, technology, and public policy. She's the Chief Medical Officer at Adia Health, where she leads work on AI-powered diagnostic tools, and a Senior Fellow at Independent Women's Forum, where she's shaking up the national conversation with her new paper, Rethinking Vaccine Policy: A Case for Humility, Precision, and Parental Partnership.Dr. Yohanan trained at Dartmouth, Brown, Harvard, and Stanford, and has taught at UCSF and Stanford. She's a nationally recognized voice on evidence-based medicine, having worked on issues from pain management and mental health parity to the opioid crisis and healthcare technology reform.In this conversation, we delve into how public health can rebuild trust by respecting parents, embracing precision, and utilizing technology wisely.Subscribe on Apple Podcasts, Spotify, or YouTube, and visit VanceGinn.com and my handle on X for more pro-growth policy content that doesn't pull punches.

This special episode of Interchange Recharged brings together finance, law, and technology leaders shaping the path to commercial carbon capture. Host Sylvia Leyva Martinez explores how capital, regulation, and innovation are converging to turn early-stage CCUS projects into bankable reality.The conversation opens with Omer Farooq, Head of Sustainable Asset Finance at Bank of America, on how one of the world's largest banks is approaching carbon capture — from financing first-of-a-kind projects to assessing new business models and risk structures. Omer explains why point-source capture is already investable, why direct air capture still has hurdles to clear, and why incentives like 45Q remain the backbone of the economics. “Policy drives energy,” he says, “and transport and permitting are the next frontiers.”Next, Liz McGinley, Partner at Bracewell LLP, joins to unpack the evolving U.S. regulatory landscape. She discusses the expanded 45Q tax credit, the lingering uncertainty around the Greenhouse Gas Reporting Program, and why the slow pace of pipeline permitting has become a bottleneck for deployment. Yet, she says, investor confidence is growing fast — driven by clarity on incentives and insurance mechanisms to manage geological risk.Finally, Shahul Hameed, Vice President of Global Oil & Gas Measurement Instrumentation at Emerson, explains how technology is catching up with policy. He shares how decades of oil and gas expertise are being repurposed for CO₂ transport and storage, and how automation, measurement accuracy, and data integrity are helping to de-risk projects. From AI-driven analytics to mass-based metering, Shahul outlines how precision is becoming the new currency of CCUS.From finance and legal frameworks to field-level innovation, this episode captures the mood on the ground in Houston — one of optimism, collaboration, and rapid evolution. As Sylvia concludes, “Finance follows certainty. The incentives are there, the technology is advancing, and the industry is learning fast.”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out this awesome Encore show from October 11, 2023 on today's readings. Bible Study: (1:53) Jon 4:1-11 How do we talk about Jonah in a way that kids don't lose respect for the Scriptures? Father discusses the difficulty of forgiveness Lk 11:1-4 Father breaks down The Our Father Letters (20:30) - Policy about dogs in Church (21:51) - Too often the music at mass is too loud! (27:20) - Our daughter wants to get confirmed Catechism for adults: https://www.usccb.org/sites/default/files/flipbooks/uscca/files/assets/basic-html/page-23.html (28:55) - Lutheran beliefs about the Eucharist Word of the Day (33:31) Callers: (36:33) - What do you think about me giving everything to charity instead of my family? (38:51) - Grandson asked why you have to confess venial sins if you are forgiven by going through mass? (41:47) - How to deal with family members who don't believe in the pope and what to say to them? (47:06) - Did people from the old testament have to wait to see Jesus until opened the gates of Heaven? (49:38) - Thou shall not worship strange gods vs false gods. What is the difference?

Chaos doesn't just appear—it's invited. We bring on former San Juan County Sheriff Ken Christensen to dig into how policy choices and political signals ripple into street-level realities, from cashless bail in New Mexico to nightly unrest outside ICE facilities in Portland. Ken shares why he left, what changed during his time away, and why he's running again to restore order, support officers, and make communities feel safe walking to the grocery store.We trace the timeline from the 2016 bail reform pitch to the 2017 rollout and the unintended consequences that followed: repeat offenders back on the street, rising recidivism, and a spike in officer-involved shootings. Then we zoom out to the national scene—local leaders discouraging police response, protests turning violent while officers watch from the curb, and federal agents forced to manage situations locals won't touch. Ken doesn't mince words on how leadership affects morale and outcomes: when rules are soft and rhetoric is incendiary, people test boundaries, and everyday residents pay the price.We also tackle the thorny questions: Should local police assist federal agencies like ICE? What happens when cities operate hotlines to tip off neighborhoods about federal enforcement? How do we recruit and retain good officers after years of “defund” narratives and legal uncertainty? Ken outlines concrete moves—restore qualified immunity protections, reduce red tape that punishes proactive policing, target repeat offenders consistently, and invest in the support roles and technology that actually solve crimes.If you care about public safety, police morale, crime policy, and what it takes to rebuild trust, this conversation pulls no punches and offers a road map. Listen, share with a friend who cares about safer streets, and leave a review so more people can find the show.Website: https://www.nodoubtaboutitpodcast.com/Twitter: @nodoubtpodcastFacebook: https://www.facebook.com/NoDoubtAboutItPod/Instagram: https://www.instagram.com/markronchettinm/?igshid=NTc4MTIwNjQ2YQ%3D%3D

In this episode of Longevity by Design, our host, Dr. Gil Blander, sits down with Dylan Livingston, CEO at the Alliance for Longevity Initiatives, and Dr. Brenda Eap to explore how public policy shapes the future of aging research. Dylan and Brendan share how their team pushes for legislation that supports healthy lifespan extension, aiming to bring longevity science into the center of national health priorities.Dylan and Brendan explain why policy advocacy is crucial for securing funding for research, reducing regulatory hurdles, and establishing a clear path for new therapies. They outline recent successes, including building bipartisan support in Congress and expanding access to experimental treatments in states such as Montana. Throughout their discussion, Dylan shows how effective communication,  using stories and simple analogies, helps move longevity from the lab to lawmakers' agendas.The episode closes with practical advice for listeners. Dylan highlights the power of community, clear communication, and grassroots action as tools that help turn advanced science into real-world health gains.Episode highlights:[00:00:00]: Introduction[00:01:00]: Overview of Longevity Policy and Research Funding[00:02:00]: Backgrounds and Personal Journeys into Longevity Advocacy[00:05:00]: Inspiration and Founding of Longevity Policy Organization[00:07:00]: Scientific Training and Motivation for Policy Work[00:09:00]: Mission and Approach of Longevity Advocacy Organization[00:10:00]: Policy Advocacy's Role in Advancing Longevity Research[00:12:00]: Gaps in Funding and the Importance of Government Engagement[00:13:00]: Experiences with Policy Events and Realizations about Advocacy[00:14:00]: Early Accomplishments and Congressional Engagement[00:15:00]: Building Bipartisan Support and the Longevity Science Caucus[00:16:00]: Legislative Engagement and Policy Paper Development[00:17:00]: State-Level Policy Wins and Expansion of Right to Try Laws[00:19:00]: Rationale and Strategy for State-Level Focus[00:21:00]: Plans for Geographic Expansion of Longevity Policy Initiatives[00:23:00]: Political Climate and Opportunities with the Current Administration[00:25:00]: Shifts in Federal Attitudes Toward Longevity and Healthspan[00:27:00]: Demographics, Policy Momentum, and National Health Priorities[00:29:00]: Prevention Versus Treatment: Shifting Policy Mindsets[00:32:00]: Communicating Policy Opportunities to a Wider Audience[00:34:00]: Ensuring Longevity Policy Remains Bipartisan[00:35:00]: Intersection of Policy, Science, and Public Engagement[00:37:00]: Funding and Regulatory Challenges in Longevity Research[00:39:00]: Barriers in Clinical Trials and Policy Modernization[00:40:00]: Strategies for Communicating Longevity Science to Policymakers[00:44:00]: Framing Longevity for Policy Impact and Public Understanding[00:48:00]: Future Vision and Milestones for Longevity Policy[00:51:00]: How Individuals and Organizations Can Support Longevity Advocacy[00:55:00]: Practical Longevity Advice and Episode ConclusionWe Appreciate You!As a token of our gratitude, we're excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcastFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast

Text us a comment or question!We're living longer - but not healthier. Chronic disease, obesity, cancer, and cognitive decline are skyrocketing, and most of us have been led to believe it's all about food and fitness. But there's a deeper story hiding in plain sight. In this eye-opening conversation, Coach Kevin English sits down with Dr. Nathan Donley, a cellular biologist turned environmental health researcher, to uncover the truth about the toxins all around us - and inside us. From pesticide-laden crops to chemical-filled water and everyday household products, Dr. Donley reveals how corporate profits and weak policy have created an invisible health crisis. You'll learn what these chemicals are doing to your body, how they interact with diet and lifestyle, and why prevention (not treatment) should be the future of medicine. If you've ever felt like you're doing “everything right” but still struggling to feel vibrant and strong, this episode will change the way you think about health, aging, and personal responsibility. In This Episode You'll Discover:Why chronic disease rates keep climbing - even as science advancesThe shocking truth about what's really in your food, water, and soilHow modern agriculture and corporate lobbying shape the “standard” American dietThe difference between dirt and living soil (and why it matters for your health)How long-term exposure to small amounts of toxins can sabotage your body's ability to healWhy the solution isn't a “detox” - it's systemic change and smarter choicesWhat steps you can take today to reduce exposure and reclaim control over your health About Dr. Nathan DonleyDr. Donley earned his PhD in Cell and Developmental Biology at Oregon Health and Sciences University, where he studied how toxic chemicals damage DNA and lead to cancer. Today, he works with the Center for Biological Diversity, fighting to expose the health and environmental dangers of pesticides and chemical pollution - and pushing for stronger protections for people, wildlife, and the planet.Visit https://www.biologicaldiversity.org to learn more and take action.Instagram - https://www.instagram.com/centerforbiodiv/ 

In this deeply personal and timely episode of An Educated Guest, host Todd Zipper sits down with Shaka Mitchell, Senior Fellow at the American Federation for Children. Shaka shares his compelling journey from the classroom and the courtroom into the heart of the school choice movement. He explains why his advocacy is driven by his core belief that education is the "surest way to access Whatever your version of the American dream is," and why the current system fails to deliver that promise for too many children.The conversation delves into the necessity of educational choice as a policy matter, focusing on how parents are demanding better options for their children. Shaka offers a powerful, community-based perspective on why resources should follow the student and how choice can serve as the critical mechanism to access the right education. This episode is a must-listen for anyone seeking to understand the moral and strategic imperative driving the school choice revolution today.Key Takeaways from this Episode:The School Choice Imperative: Shaka's belief that a child's background should not determine the quality of their education.Policy and Practice: How Shaka's legal and educational experience informs his work in shaping state-level policy.The Role of Parents: A discussion on the rising power of parents and their demand for better educational options.Finding the Right Fit: Why a one-size-fits-all model doesn't work, and how choice creates the opportunity for a better educational experience for every single child.About Our Guest:Shaka Mitchell is a Senior Fellow at the American Federation for Children. A former educator and lawyer, Shaka has dedicated his career to driving educational reform and expanding opportunities for children in underserved communities.

Black people are four more times likely to be sectioned compared to the general population according to the mental health charity, Mind. That number is rising, but why?As the new Mental Health Act 2025 rumbles through Parliament, hoping to address some of these inequalities, we meet Shocka, a former member of the boyband Marvel. He has been sectioned four times and tells us what time in a psychiatric unit can feel like. Kadra Abdinasir, Associate Director of Policy for the Centre for Mental Health, joins us too to talk about why a framework around racial inequalities is crucial to improved mental health outcomes for black people and other minority groups, and the worry she and others have that it won't be included as a priority in the Act and legally binding.Actress and model Ellie Goldstein has made a strong start in this year's Strcitly Come Dancing competition with her professional partner, Vito Coppola. We go behind the fake tan and sequins with Sam, who has learning disabilities, and his dance teacher, Jo Banham from Sensational Care Provisions, to find out how the duo might be pacing themselves, the moves that might not work for them and how they are managing to learn a new dance every week.Presented by Emma Tracey with Kirsteen Knight Sound mixed by Dave O'Neill Produced by Emma Tracey and Kevin Satizabal Carrascal Series producer is Beth Rose Editor is Damon Rose

About this episode: Apprenticeships offer the unique opportunity to earn money while learning in-demand skills—and they can be a useful public health intervention, diverting young people away from violence and poor choices. In this episode: Maryland State Senator Cory McCray opens up about his own apprenticeship experience and how earn-while-you-learn opportunities can transform young people's lives. Guest: Cory V. McCray is a state senator representing Maryland's 45th District. He is also an electrician, an entrepreneur, and the author of “The Apprenticeship That Saved My Life: Guidebook to Navigating the Earn-While-You-Learn Opportunity of a Lifetime”. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: The Apprenticeship That Saved My Life: Guidebook to Navigating the Earn-While-You-Learn Opportunity of a Lifetime—Morgan James Publishing Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Tuesday marks two years since Hamas's attack on Israel on Oct. 7, 2023. Since then, Israel has decimated Gaza in what many independent organizations are calling a genocide and attacked several countries in the region. How have all of these events impacted the world? FP columnist Stephen M. Walt sits down with Ravi Agrawal to share his take. John J. Mearsheimer and Stephen M. Walt: The Israel Lobby and U.S. Foreign Policy Stephen M. Walt: Meet the New Middle East, Same as the Old Middle East Steven A. Cook: The Delusions Driving U.S. Policy in the Middle East Pankaj Mishra: How Gaza Shattered the West's Mythology Emma Ashford: What Was the Tipping Point on Gaza? John Haltiwanger: Why Israel's War in Gaza Has Been So Deadly for Journalists Learn more about your ad choices. Visit megaphone.fm/adchoices

In El Paso, a three-judge panel is hearing a legal challenge to Texas' new congressional map. Eleanor and Matthew talk to voting rights expert Justin Levitt about the case.

Country Music Star Takes Swing at President Trump's Key Policy | Mundo Clip 10-7-25See omnystudio.com/listener for privacy information.

Legalese and logistics shouldn't stop you from living and working anywhere. In this episode, we unpack the confusing stuff: work-from-anywhere policies vs. hire-from-anywhere roles, W-2 vs. 1099, employer-of-record (EOR), visas, and taxes. So you know what job listings actually mean and how to navigate them. No promises, no legal advice, just clear explanations and what to consider next.Highlights:

What happens to America’s health when Washington grinds to a halt? In this episode of The Health Advocates, we break down the latest federal government shutdown and what it means for public health agencies across the country. We explain what a shutdown actually is, drawing from past shutdowns over the last 30 years, and then dive into the immediate and long-term impacts on the CDC, FDA, NIH, and other agencies that millions of people depend on for research, vaccines, food safety, and emergency response. We also look at the political stalemate behind the shutdown, focusing on Democrats’ push to restore pending cuts to Affordable Care Act subsidies and what those cuts could mean for healthcare costs. Finally, we explore whether there’s a realistic path to resolution soon—and what’s at stake for patients and the healthcare system if Congress fails to act. Contact Our Host Steven Newmark, Chief of Policy at GHLF: snewmark@ghlf.org A podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF. We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.org Listen to all episodes of The Health Advocates on our website (https://ghlf.org/the-health-advocates) or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Steven Rinella talks with Montana Congressman Ryan Zinke. Topics discussed: Being red, white, and blue; from the military to politics; the fight for public lands; migration corridors; the Roadless Rule; delisting grizzlies; and more. Connect with Steve and The MeatEater Podcast Network Steve on Instagram and Twitter MeatEater on Instagram, Facebook, Twitter, and YouTubeSee omnystudio.com/listener for privacy information.

Episode 4830: Feuding, Factions, and MAGA Operatives Drive Trump's Antitrust Policy

In this episode, John Odermatt sits down with Sheriff Richard Mack, former sheriff of Graham County, Arizona, and founder of the Constitutional Sheriffs and Peace Officers Association (CSPOA). Sheriff Mack shares his unique perspective on the role of local law enforcement in defending civil liberties and resisting government overreach. The conversation covers recent high-profile incidents, the importance of constitutional education for law enforcement, and the power of community involvement. Sheriff Mack also addresses controversies, conspiracy theories, and the mission of CSPOA. Tune in for a thought-provoking discussion on liberty, responsibility, and grassroots action. Chapters 00:00 - Introduction & Welcome00:51 - About Sheriff Mack02:56 - The Mission: Protecting Civil Rights04:36 - Recent Events & Gun Control Debates09:45 - The Role of Law Enforcement13:27 - Analyzing the Charlie Kirk Case18:35 - Gun Violence, Policy, and Constitutionality22:00 - Community, Spirituality, and Social Division27:00 - The Power of Local Government29:20 - CSPOA's Mission & Upcoming Events32:13 - Addressing Controversies & Slander35:09 - Where to Find Sheriff Mack36:14 - Show Wrap-Up & Supporter Info38:00 - Closing Thoughts Links Sheriff Mack's website & books: https://cspoa.org Support the show: https://patreon.com/lionsofliberty | https://lionsofliberty.locals.com Care about your liberty and future? Don't miss the Expat Money Online Summit, October 10–12, hosted by Mikkel Thorup of the Expat Money Show. It's free to attend and features top experts on protecting wealth, securing second residencies, lowering taxes, and owning property abroad. Upgrade for lifetime replay access and VIP panels with promo code LIONS for 20% off. Stop paying health insurance companies your hard-earned dollars. Go to Join Crowd Health now and experience freedom from health insurance. Healthcare for under $100! You get access to a team of health bill negotiators, low cost prescription and lab testing tools, as well as a database of low cost high quality doctors vetted by CrowdHealth. And what if something major happens? You pay the first $15K, then the Crowd steps in to help fund the rest.. Go to Join Crowd Health and get started for $80/mo for the first three months by using promo code LIONS at sign-up. We have a new show on Lions of Liberty! The Politicks Podcast! Be sure to subscribe to the standalone Politicks Podcast feed. This is the absolute best way to support the show! Listen and subscribe on Apple Podcasts and Spotify. And remember, they're all Blood Suckers! Subscribe to John's Finding Freedom Show solo feed to listen to “Pursuit of Freedom,” which is a new podcast series where John shares the highs and lows of his entrepreneurial journey. Listen and Subscribe on Apple Podcasts and Spotify. Follow the Lions of Liberty: Twitter Rumble YouTube Instagram Telegram Get access to all of our bonus audio content, livestreams, behind-the-scenes segments and more for as little as $5 per month by joining the Lions of Liberty Pride on Patreon OR support us on Locals! Check out our merchandise at the Lions of Liberty Store for all of our awesome t-shirts, mugs and hats! Learn more about your ad choices. Visit megaphone.fm/adchoices

From high-speed rail to electric cars to batteries to AI, it's clear that China can operate with incredible speed at massive scale. Can the US still compete?We sat down with Dan Wang, a Research Fellow at the Hoover Institution and the author of “Breakneck: China's Quest to Engineer the Future” to discuss. Timecodes: 0:00  Introduction1:36   Lawyers vs. Engineers: Cultural and Economic Differences4:06  Urban and Rural Life: Comparing Infrastructure7:20  Barriers to Progress: Regulation and Governance11:00  Industrial Policy and Public-Private Partnerships14:20  The Double-Edged Sword of Legal and Engineering Mindsets16:50  Social Engineering and Policy in China23:00  Competition, Intellectual Property, and Business Culture27:10  Manufacturing, Scale, and Global Supply Chains36:00  Lessons from Japan and Korea41:30  Complacency, Quality, and the Future of Competition48:45  Strategic Resources and Industrial Policy54:00  Foreign Policy: Engineering Diplomacy vs. Alliances59:00  Taiwan, Demographics, and the Future of US-China Relations Resources:Follow Dan on X: https://x.com/danwwangRead Dan's blog: https://danwang.co/Buy Breakneck on Amazon: https://www.amazon.com/dp/1324106034/Follow Steven on X: https://x.com/stevesi Stay Updated:Find a16z on XFind a16z on LinkedInListen to the a16z Podcast on SpotifyListen to the a16z Podcast on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode of the Coin Stories News Block powered exclusively by Ledn, we cover these major headlines related to Bitcoin, macroeconomics, and global finance: JPMorgan Labels Bitcoin as the “Debasement Trade," Lifts BTC Fair Value to ~$165k Global Debt Hits $338T -- Hard Money Outperforms Treasury to Exempt Bitcoin from 15% Corporate Tax Ray Dalio Shares Criticism of Bitcoin Privacy, Security, Central Bank Adoption Robinhood Lists Strategy's Preferred Equity Products  ---- The News Block is powered exclusively by Ledn – the global leader in Bitcoin-backed loans, issuing over $9 billion in loans since 2018, and they were the first to offer proof of reserves. With Ledn, you get custody loans, no credit checks, no monthly payments, and more. My followers get .25% off their first loan. Learn more at www.ledn.io/natalie  ---- Read every story in the News Block with visuals and charts! Join our mailing list and subscribe to our free Bitcoin newsletter: https://thenewsblock.substack.com  ---- References mentioned in the episode: Treasury Clarifies Guidance on CAMT Policy Treasury to Exempt BTC from CAMT on Unrealized Gains Senator Lummis' Tweet on CAMT Guidance  Michael Saylor's Tweet on CAMT Guidance Charlie Bilello's Tweet on Gold & BTC Performance Bitcoin Rises to Record Amid the “Debasement Trade”  JPMorgan Labels Bitcoin as the “Debasement Trade” IIF: Global Debt Has Increased to $338 Trillion  JPMorgan Says that Bitcoin's Fair Value is $165K CNBC Headline Calls Bitcoin a Safe-Haven Asset Robinhood Lists Strategy's Preferred Equity Products Robinhood Lists Strategy's Preferreds in Platform First  Vlad Tenev's Tweet on Listing Strategy's Preferreds Ray Dalio's Recent Comments on Bitcoin ---- Upcoming events: Bitcoin 2026 will be here before you know it. Get 10% off Early Bird passes using the code HODL: https://tickets.b.tc/event/bitcoin-2026?promoCodeTask=apply&promoCodeInput=  Your Bitcoin oasis awaits at Camp Nakamoto: A retreat for Bitcoiners, by Bitcoiners. Code HODL for discounted passes: https://massadoptionbtc.ticketspice.com/camp-nakamoto      ---- This podcast is for educational purposes and should not be construed as official investment advice. ---- VALUE FOR VALUE — SUPPORT NATALIE'S SHOWS Strike ID https://strike.me/coinstoriesnat/ Cash App $CoinStories #money #Bitcoin #investing

Visit our website:https://www.thewealthwarehousepodcast.com/New policy in force, now what? Dave and Paul walk through the first moves after your IBC policy goes active. From “slow your roll” capitalizing, to trading out high-interest debt, to building an emergency reserve inside your system, they map a practical sequence so you don't chase loans just to “do something.”They also cover spotting real opportunities (and avoiding FOMO), expanding your system with additional policies, redirecting cash flow, and a quick primer on smarter ways to think about 529 plans.Becoming Your Own Banker by Nelson Nash:https://infinitebanking.org/product/becoming-your-own-banker/ref/46/Episode Highlights:0:00 – Teaser1:16 – Delayed start & plumbing mishap4:08 – One policy to start; why “now what?” is normal5:32 – “Slow your roll”: capitalizing and building liquidity6:21 – Loans don't add value by themselves7:06 – Trade out high-interest debt; snowball/“velocity banking”7:51 – Trend: eagerness to borrow vs. proper capitalization10:30 – Which debt first? Amortization vs. smallest balance11:59 – Freeing monthly cash flow with the snowball12:54 – Look for opportunities without rushing; be choosy17:25 – Cautionary tales: real estate pitches & protecting capital18:22 – More policies over time: expanding the system 22:05 – The 95/5 rule: focus on earning more, not just cutting25:45 – Kids' policies: small premiums, long runway26:41 – Premiums vs income, lifestyle creep, staying responsible28:48 – Recap: capitalize → redirect → seek opportunities → expand29:30 – 529s: usage today vs. assumptions about tomorrow32:20 – CTA: email, reviews, and sharingABOUT YOUR HOSTS:David Befort and Paul Fugere are the hosts of the Wealth Warehouse Podcast. David is the Founder/CEO of Max Performance Financial. He founded the company with the mission of educating people on the truths about money.David's mission is to show you how you can control your own money, earn guarantees, grow it tax-free, and maintain penalty-free access to it to leverage for opportunities that will provide passive income for the rest of your life.Paul, on the other hand, is an Active Duty U.S. Army officer who graduated from Norwich University in 2002 with a B.A. in History and again in 2012 with a M.A. in Diplomacy and International Terrorism. Paul met his wife Tammy at Norwich.As a family, they enjoy boating, traveling, sports, hunting, automobiles, and are self-proclaimed food people.Visit our website:https://www.thewealthwarehousepodcast.com/Catch up with David and Paul, visit the links below!Website: https://infinitebanking.org/agents/Fugere494 https://infinitebanking.org/agents/Befort399LinkedIn: https://www.linkedin.com/in/david-a-befort-jr-09663972/...

The Trump administration says Minnesota is in violation of Title IX due to a policy that lets transgender student athletes compete in sports consistent with their gender identity. Title IX is a federal law that prohibits discrimination on the basis of sex in programs that receive federal funding. Administration officials say Minnesota must end its policy by Thursday or risk losing federal education aid. Previously, Minnesota Attorney General Keith Ellison has argued that the policy is consistent with Minnesota's human rights laws.Joining MPR News host Nina Moini to break this down is Jessica Heiser, a Minnesota-based education civil rights lawyer with Imprint Legal Group.

Cities around the Bay Area have been debating how to handle people camping in public places or living in RVs. Oakland may follow suit.

This show has been flagged as Explicit by the host. New hosts Welcome to our new hosts: Wojciech, Major_Ursa. Last Month's Shows Id Day Date Title Host 4456 Mon 2025-09-01 HPR Community News for August 2025 HPR Volunteers 4457 Tue 2025-09-02 doodoo deuce Jezra 4458 Wed 2025-09-03 Creating an animation in Powerpoint Dave Hingley 4459 Thu 2025-09-04 How I got into tech Wojciech 4460 Fri 2025-09-05 Arthur C. Clarke Ahuka 4461 Mon 2025-09-08 Battle of the mic's Lee 4462 Tue 2025-09-09 HPR Beer Garden - Intro and Dessert Stouts Kevie 4463 Wed 2025-09-10 Software Freedom Day NJ, briefly. murph 4464 Thu 2025-09-11 Replacing the Trackpad on my Laptop Claudio Miranda 4465 Fri 2025-09-12 Playing Civilization V, Part 3 Ahuka 4466 Mon 2025-09-15 HPR Music project - Walking tune to(wards) a friend FredBlack 4467 Tue 2025-09-16 A small Odoo usage intro and a larger technical bit Jeroen Baten 4468 Wed 2025-09-17 AI Trap and Fix Archer72 4469 Thu 2025-09-18 Disagree With Me - 3 Statements About Life Living Antoine 4470 Fri 2025-09-19 HPR is twenty years old today. Lee 4471 Mon 2025-09-22 Ti-82 Makes Music and Password Manager operat0r 4472 Tue 2025-09-23 Cheap Yellow Display Project: Introduction to the Cheap Yellow Display Trey 4473 Wed 2025-09-24 HPR Beer Garden 2 - Session IPA Kevie 4474 Thu 2025-09-25 Hacker Poetry - 001 Major_Ursa 4475 Fri 2025-09-26 The true audio file for walking tune to(wards) a friend FredBlack 4476 Mon 2025-09-29 Does AI cause brain damage? Trollercoaster 4477 Tue 2025-09-30 doodoo 3 a deuce plus 1 Jezra Comments this month These are comments which have been made during the past month, either to shows released during the month or to past shows. There are 22 comments in total. Past shows There are 4 comments on 4 previous shows: hpr4393 (2025-06-04) "Journal like you mean it." by Some Guy On The Internet. Comment 1: Archer72 on 2025-09-01: "Journaling" hpr4442 (2025-08-12) "Orthopedagogiek - what it is." by Manon. Comment 4: Manon Fallon on 2025-09-07: "Thank you" hpr4445 (2025-08-15) "doodoo one" by Jezra. Comment 3: Windigo on 2025-09-03: "Singular vs plural functions" hpr4453 (2025-08-27) "IPv6 for Luddites" by beni. Comment 5: Paulj on 2025-09-09: "Fantastic show - thank you" Comment 6: Dave Morriss on 2025-09-09: "I was surprised to find that my ISP offers IPv6" This month's shows There are 18 comments on 10 of this month's shows: hpr4456 (2025-09-01) "HPR Community News for August 2025" by HPR Volunteers. Comment 1: candycanearter07 on 2025-09-01: "show doubt"Comment 2: أحمد المحمودي on 2025-09-12: "Pronouncing my name"Comment 3: Ken Fallon on 2025-09-16: "Can I have an example" hpr4459 (2025-09-04) "How I got into tech" by Wojciech. Comment 1: Archer72 on 2025-09-01: "First show"Comment 2: Antoine on 2025-09-04: "Welcome! "Comment 3: Henrik Hemrin on 2025-09-04: "Thanks and welcome"Comment 4: Andrew on 2025-09-04: "Excellent first show..."Comment 5: paulj on 2025-09-09: "Welcome, and thanks!" hpr4461 (2025-09-08) "Battle of the mic's" by Lee. Comment 1: candycanearter07 on 2025-09-12: "Interesting dive into a topic not thought about often!" hpr4462 (2025-09-09) "HPR Beer Garden - Intro and Dessert Stouts " by Kevie. Comment 1: T.A.Spinner on 2025-09-13: "Your thoughts on hefeweizens?" hpr4466 (2025-09-15) "HPR Music project - Walking tune to(wards) a friend" by FredBlack. Comment 1: candycanearter07 on 2025-09-25: "unique idea for a show!" hpr4470 (2025-09-19) "HPR is twenty years old today. " by Lee. Comment 1: quvmoh on 2025-09-20: "congrats"Comment 2: ClaudioM on 2025-09-26: "Happy 20th Anniversary!" hpr4471 (2025-09-22) "Ti-82 Makes Music and Password Manager" by operat0r. Comment 1: candycanearter07 on 2025-09-25: "TI calc history" hpr4472 (2025-09-23) "Cheap Yellow Display Project: Introduction to the Cheap Yellow Display " by Trey. Comment 1: Archer72 on 2025-09-23: "Following the series" hpr4473 (2025-09-24) "HPR Beer Garden 2 - Session IPA" by Kevie. Comment 1: Ken Fallon on 2025-09-24: "FLOSS Beer Tracker " hpr4476 (2025-09-29) "Does AI cause brain damage?" by Trollercoaster. Comment 1: Trey on 2025-09-29: "Excellent episode"Comment 2: Trollercoaster on 2025-09-30: "Re: Excellent episode" Mailing List discussions Policy decisions surrounding HPR are taken by the community as a whole. This discussion takes place on the Mailing List which is open to all HPR listeners and contributors. The discussions are open and available on the HPR server under Mailman. The threaded discussions this month can be found here: https://lists.hackerpublicradio.com/pipermail/hpr/2025-September/thread.html Events Calendar With the kind permission of LWN.net we are linking to The LWN.net Community Calendar. Quoting the site: This is the LWN.net community event calendar, where we track events of interest to people using and developing Linux and free software. Clicking on individual events will take you to the appropriate web page.Provide feedback on this episode.

From May 2, 2023: Generative AI products have been tearing up the headlines recently. Among the many issues these products raise is whether or not their outputs are protected by Section 230, the foundational statute that shields websites from liability for third-party content.On this episode of Arbiters of Truth, Lawfare's occasional series on the information ecosystem, Lawfare Senior Editor Quinta Jurecic and Matt Perault, Director of the Center on Technology and Policy at UNC-Chapel Hill, talked through this question with Senator Ron Wyden and Chris Cox, formerly a U.S. congressman and SEC chairman. Cox and Wyden drafted Section 230 together in 1996—and they're skeptical that its protections apply to generative AI. To receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.

Several high-profile cases are on the docket as the supreme court returns from summer recess, many of which will provide a definitive ruling on whether President Trump overstepped the boundaries of his executive powers by ordering wide-ranging tariffs. FOX News Senior National Correspondent Rich Edson joins the Rundown to break down what those cases are, from the legality of President Trump's tariff policies to birthright citizenship being called into question for the first time in over a century. Later, Medicare director at the Centers for Medicare and Medicaid Services, Chris Klomp breaks down President Trump's deal with Pfizer, and what it means for patients across the country. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode examines real-world data from a 12-year-old indexed universal life insurance policy. We track how the policy performed despite significant changes to its original parameters. The case study reveals insights about IUL resilience and flexibility. The policy started with a 12% cap rate and 2% floor on the S&P 500. Over the 12 years, the cap rate dropped to 7.75%, yet the policy still achieved an average return of 7.37%. This exceeded the original 6% assumption used in the planning process. We break down the frequency of hitting caps versus floors over the policy's lifetime. The data show that the policy hit the floor 18% of the time and fell within the moderate 2-7% range only 12% of the time. Most performance landed at higher levels. The episode explains how insurance companies set cap rates and why they change over time. We cover the role of bond yields and options pricing in determining these rates. The discussion clarifies why cap rate adjustments aren't arbitrary profit-grabs by insurers. This particular policy stopped receiving premium payments after just two years. Despite this dramatic departure from the original plan, the policy continues to grow and remain viable. We examine the options available when funding plans undergo a complete change. The performance data offers a comparison of IUL versus whole life insurance during the same period. While cap rates declined for IUL policies, they rebounded more quickly than whole life dividend increases. The comparison highlights different product characteristics. ______________________________ Ready to explore whether indexed universal life insurance might work for your situation? Contact us to discuss your specific needs and see how IUL could fit into your financial strategy.

Several high-profile cases are on the docket as the supreme court returns from summer recess, many of which will provide a definitive ruling on whether President Trump overstepped the boundaries of his executive powers by ordering wide-ranging tariffs. FOX News Senior National Correspondent Rich Edson joins the Rundown to break down what those cases are, from the legality of President Trump's tariff policies to birthright citizenship being called into question for the first time in over a century. Later, Medicare director at the Centers for Medicare and Medicaid Services, Chris Klomp breaks down President Trump's deal with Pfizer, and what it means for patients across the country. Learn more about your ad choices. Visit podcastchoices.com/adchoices

I got an email from Audrey Walleser, a PhD candidate in American Law and Policy who has 25 years of professional experience in constitutional law, political structure, statutory authority, and regulatory integrity. She had quite a bit to say about the Constitutionality of the AFFTRA and its goals to set minimum rates and driver pay in the Trucking industry. She is going to join me to walk through the civic process for movements like this and explain how to get things done through the government. All of our Links: https://beacons.ai/blueribbonlogistics Pittsburgh Power: https://pittsburghpower.com Podcast Website: https://www.blueribbonlogistics.com/podcast Blue Ribbon Facebook: https://www.facebook.com/blueribbonlogistics Blue Ribbon Website: https://www.blueribbonlogistics.com Blue Ribbon Blog: https://www.blueribbonlogistics.com/blog DRIVE FOR US: https://www.blueribbonlogistics.com/drive-for-us iTunes Link: https://podcasts.apple.com/us/podcast/blue-ribbon-podcast/id1031752967

The Department of Homeland Security has started a program targeting unaccompanied children for voluntary deportation. How the Chevron refinery fire in El Segundo will squeeze Southern California’s jet fuel supply. The Dodgers and Phillies face off in game one of NLDS today. Plus, more. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.com Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency!Support the show: https://laist.com

Joe and Kyle debrief a hometown Dreamshadow Transpersonal Breathwork weekend in Breckenridge, then sketch the next chapter for Psychedelics Today: a community-centric model (Navigators) that bundles education, live streams, book and film clubs, and small-group access. They kick around the big “creativity + psychedelics” question, contrast subjective “I feel creative” with objective task performance, and highlight new research—from DMT's potential in stroke recovery to breathwork's measurable effects. They wrap with quick hits on MAPS leadership, state policy moves, and what's coming up at PT this fall. Highlights & takeaways Breathwork > substance? A reminder that profound states are accessible without drugs; benefits of facilitating at home (rested facilitators = safer, better containers). What is “shamanism,” really? A functional frame: non-ordinary states, interaction with the unseen, and service (healing/divination). Community > one-off courses: PT is shifting toward a monthly membership model to keep prices accessible, deepen relationships, and sustain more free content. Creativity debate: Double-blind study (DMT + harmine vs harmine vs placebo) suggests impaired convergent thinking despite increased felt creativity; how to define and measure “creativity” fairly, and other research outcomes might tell a different story. Whitehead & novelty: A quick tour through Alfred North Whitehead's notion of “creativity” as the principle of novelty—useful language for mapping psychedelic insight to real-world change. Neuro + clinical frontiers: DMT for stroke (animal models): BBB stabilization and reduced neuroinflammation signal a promising adjunct to current care. Cluster headaches: Emerging reports on short-acting DMT for rapidly aborting cluster cycles; more data coming soon. Breathwork science: New imaging work associates music-supported hyperventilatory breathwork with blissful affect and shifts in blood flow. News & culture mentioned MAPS leadership: Betty Aldworth & Ismail (Izzy) Ali named permanent Co-Executive Directors. Policy snapshots: Colorado Natural Medicine Board recommending ibogaine (with Nagoya-compliance requirement); Alaska signature gathering; Massachusetts activity. Media & scene: Hamilton's recent appearances; contamination concerns in some “psilocybin” products; “psychedelics tick far more neurons than expected” paper; mixed findings for postpartum depression.

**Free Guide for Listeners:** Boost your practice's cash flow and reduce denials with our step-by-step **Eligibility & Billing Verification Training Guide.**  Download it here → https://natrevmd.com/eligibility-billing-verification/Starting October 1st, Cigna is rolling out a controversial “R49” policy that automatically down-codes higher-level E/M visits—cutting physician reimbursement even when documentation fully supports the billed level. In this episode of the NatRevMD Podcast, Dr. Heather Signorelli, DO, breaks down what this means for your practice, how ICD-10 codes and E/M guidelines intersect, and why the California Medical Association is fighting back. You'll learn:

Live from the LIMRA Annual Conference, host Paul Tyler and guest host, Tom Rios explore the future of carrier communications with Stephanie Warren and Tim Mader of O'Neil Digital Solutions. The conversation looks beyond today's PDFs to a unified, intelligent platform where print and digital are orchestrated together—with auto-failover (email → mail), real-time delivery confirmation for agents, and 10-year, regulation-ready audit trails.  They sketch what's next: dynamic, personalized content (QR codes, agent video intros), event-triggered journeys (policy issued, first annuity payment, claim payout), and template consolidation that unlocks governance and speed. Most importantly, they reframe communications as a revenue and referral moment—turning required documents into measurable CX wins while staying compliant. Learn more at  

Wil welcomes guest Ken Stemke, owner of Main Street Social in Libertyville, IL, an upscale Italian-American restaurant with its own wine label. Ken traces his hospitality spark to bussing tables in high school, then a 35-year career in banking that armed him with the financial discipline many restaurants lack. He shares how a seasoned team, empowerment, and a recent, internally driven menu refresh (60+ dishes tested) improved culture and guest experience. The convo dives into COVID cash-flow planning, POS frustrations, the importance of listening to staff and guests, policy headwinds like tip-credit changes, rising costs/tariffs, tech overreach, and why independent restaurants—and local coalitions—are essential to community life. Key Takeaways Banking → hospitality advantage: Ken's finance/accounting background gave him crucial cash-flow and planning skills most operators need but often lack. Seasoned staff pays off: With servers averaging ~40 in age and long tenures, May Street Social avoids much of the turnover drama. Empowerment drives innovation: Shifting decision-making to loyal team members led to a broad menu refresh without outside consultants. Manufacturing mindset: Treat each dish like a mini job—know costs, margins, and process control just as in production. Plan for storms: During COVID, Ken worked off daily cash-flows and prebuilt “Plan A/B/C” responses to policy changes. Policy ripple effects: Eliminating the tip credit (e.g., in Chicago) raises labor costs significantly and can hurt independents more than chains. Tariffs & uncertainty pinch demand: Cost shocks (produce, glass, wine) and scary headlines can temporarily depress traffic. Right-sized tech: Restaurants should resist feature bloat; deploy only tools that simplify ops (Ken is doubling down on using Schedulefly fully). POS matters: Weak reporting and lack of integrations create friction; handhelds and better data can smooth service pacing. Community is the moat: Independent restaurants anchor local identity; forming downtown/indie coalitions amplifies marketing and advocacy.

The ability to gain major media attention can significantly impact the success of an initiative, yet some organizations consistently achieve better coverage than others. Understanding how journalists and producers at leading U.S. news networks select stories for broadcast is crucial for anyone seeking media coverage. Often, small adjustments in the approach can determine whether a media pitch hits the target or misses the mark.In this special conversation with two senior media and policy insiders who operated at the highest levels of U.S. politics, you'll discover the mindset and specific mechanisms for significantly increasing your chances of gaining major media coverage of your initiatives and priorities.MaryAlice Parks, former ABC News White House Correspondent, and Mark Bayer, former U.S. Senate Chief of Staff and faculty author of eCornell's “Media Strategy for Policy and PR” certificate program, will share proven insider approaches for earning major media coverage.What You'll Learn:What network news producers look for when deciding which stories to coverHow to package your pitch for network news coverage so it stands out from the crowdCommon mistakes to avoid if you want to earn national media coverage of your issue or priorityInsight into pitches that succeeded in earning network TV coverage----Turn powerful communication into decisive leadership. The 18-month, mostly online Executive Master of Public Administration (EMPA) equips working professionals to lead across sectors with clarity and confidence. Get EMPA details here https://publicpolicy.cornell.edu/masters/mpa/empa/

There's a growing call for mandatory national service in Canada — asking 18- to 30-year-olds to spend a year in public health, the environment, youth services, civil protection, or the military. Esprit de Corps editor Scott Taylor says it could strengthen citizenship and even help the Armed Forces. Policy expert David McLaughlin argues it's a way to build unity but warns it won't come cheap. Seventeen-year-old Jaden Braves pushes back, saying young people need to shape the program themselves.

Today on the show the Head of Instagram explains how they keep teens safe on the platform. However I think we all know that once you hit 3 billion monthly active users, you need to figure out how to get to 4 billion, and teens who don't have Instagram are the perfect potential audience. Also Sarah Wynn Williams, former Director of Policy at Facebook, explains how Meta targets ads to vulnerable teens and it's disgusting. Additionally Ashley Coffey and I get into this week's AI news, including social media apps with feeds that are 100% AI. Links:Instagram: Adam Mosseri on Teens (Instagram)Meta: Sarah Wynn Williams on 60 Minutes (YouTube) AI News:Meta: Meta plans to sell targeted ads based on data in your AI chats (TechCrunch)AI apps with social media feeds - Meta AI app gets Vibes and ChatGPT launches SoraSign Up for The Weekly Email Roundup: NewsletterLeave a Review: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Me on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@danielhillmedia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For financial markets and economists, the main near-term challenge of the US government shutdown is a lack of data. The longer the shutdown rumbles on, the larger the potential negative economic consequences. In Europe, we are moving firmly into budget season, putting fiscal policies at the top of the agenda. In Asia, it is all about central bank meetings, with the Philippines, Thailand and New Zealand all set for rate cuts in the week ahead. Chapters: US: 02:13, Europe: 08:06, Asia: 13:34. 

Our Chief China Equity Strategist Laura Wang discusses how China's new approach to economic development is transforming domestic industries and reshaping the global investment landscape.Read more insights from Morgan Stanley.----- Transcript ----- Welcome to Thoughts on the Market. I'm Laura Wang, Morgan Stanley's Chief China Equity Strategist.Today – a consequential shift in China's economic policy is set to reshape domestic markets and send ripples across the global economy.It's Thursday, October 2nd at 2pm in Hong Kong.If you're an investor, it's important to understand China's new approach to economic development. The government's policies to drive a recovery from an economic slump are changing the rules of competition, profitability and growth. This affects Chinese companies, and in turn global supply chains and investment flows.Let's start with the term involution – what is it? In China, involution describes a cycle of excessive competition—think companies fighting for market share by slashing prices, ramping up production, and eroding profits, often to the point where nobody wins. The government's anti-involution campaign is a direct response to this problem.What factors prompted the launch of this anti-involution initiative? Since 2021, China has faced mounting deflationary pressures—falling prices, a housing market slump, and a surge in manufacturing investment that led to overcapacity. The September 2024 policy pivot began to address these issues, and in mid-2025 the government launched a more targeted anti-involution campaign. This phase focuses on reducing excessive competition and restoring pricing power through market-based consolidation.As we assess the potential effectiveness of China's anti-involution policy, our base case projects China's return on equity (ROE) to reach 13.3 percent by 2030, up from a cycle low of 10 percent in May 2024 and 11.6 percent by July 2025. In a bullish scenario, decisive reforms and demand-side stimulus could push ROE as high as 16.3 percent.We also expect earnings growth to accelerate, with our base case showing an annual growth rate (CAGR) of 7.6 percent in 2025, rising to 11.1 percent by 2027. We forecast valuations to normalize towards 12–13x forward price-to-earnings, in line with emerging market peers, but this could re-rate higher if reforms succeed.In terms of investment opportunities, we believe the EV Batteries industry will benefit the most from the Chinese government's anti-involution efforts. It's got strong policy support, cutting-edge technology, and a market that's consolidating fast—meaning the days of low-quality and excess capacity are fading. We're seeing a shift toward long-term, sustainable growth. Steel and Cement are industries where the state has a strong hand and capacity controls are well established. These factors help stabilize the market and open the door for steady gains. Finally, Airlines. While the industry has faced persistent losses, there isn't a[n] oversupply of seats, and regulatory coordination is strong. With the right reforms, Airlines could be poised for a significant turnaround.The sectors best positioned to benefit from China's anti-involution strategy are more domestically oriented. But this policy is bound to have global implications. And the ripples will likely extend to global supply chains, especially in Materials, Chemicals and Autos.Looking ahead, the pace and success of anti-involution will depend on further structural reforms, demand-side support, and the ability to digest industrial credit risks gradually. The upcoming 15th Five-Year Plan could bring more clarity on tax, social welfare, and local government incentives.So, what should investors be paying attention to? China's anti-involution campaign is more than a policy tweak—it's a recalibration of how the country balances growth, innovation, and sustainability. The key is to track sector-level reforms, watch for signs of consolidation, and focus on companies with strong fundamentals and policy tailwinds.Thanks for listening. If you enjoy the show, please leave us a review wherever you listen and share Thoughts on the Market with a friend or colleague today.

Ben, Marc, and Erik Torenberg are joined by Brian Schimpf, Co-Founder & CEO of Anduril, and Chris Power, Founder & CEO of Hadrian. Together, they dig into America's defense production gap: why the U.S. can out-innovate but not out-produce—and what it will take to turn that around.They discuss why U.S. war games show we run out of munitions in a week, the myth of “exquisite-only” systems, how to rebuild industrial capacity with software-led automation, financing factories like data centers, and what it takes to create real deterrence in a Taiwan scenario. Timecodes: 0:00 Introduction0:27 Technical Superiority vs. Industrial Scale  3:59 The Decline of US Manufacturing  7:23 Challenges in Onshoring & Skilled Labor  13:27 Supply Chains & Rare Earths  15:34 Automation, Software, and Catching Up  17:15 Complexity of Modern Production  23:34 Strategic Policy & Industrial Planning  26:37 Regulatory Barriers & State vs. Federal Roles  35:27 Talent, Data Centers, and Financial Engineering  38:33 China's Industrial Policy & US Response  46:07 US Manufacturing, National Security, and the China Challenge  52:00 Demographics, Long-Term Outlook, and Closing Thoughts   Resources: Find Chris on X: https://x.com/chris_powerFind Brian on LinkedIn: https://www.linkedin.com/in/bschimpf/Marc on X: https://x.com/pmarcaMarc's Substack: https://pmarca.substack.com/Ben on X: https://x.com/bhorowitz Stay Updated: Find us on X:https://x.com/a16zFind us on LinkedIn: https://www.linkedin.com/company/a16zThe views expressed here are those of the individual personnel quoted and are not the views of a16z or its affiliates. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors and may not under any circumstances be relied upon when making a decision to invest in any a16z funds. PLEASE SEE MORE HERE: https://a16z.com/disclosures/ Stay Updated:Find a16z on XFind a16z on LinkedInListen to the a16z Podcast on SpotifyListen to the a16z Podcast on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of The Health Advocates, Steven Newmark sits down with Richard (RJ) Kedziora, co-founder of Estenda Solutions, to explore the intersection of technology, data, and patient advocacy. With decades of experience in healthcare technology, RJ shares how he and his team design digital tools that help patients take control of their health while supporting providers and payers alike. They also discuss patient engagement, accessibility, and the future of artificial intelligence in healthcare. Whether you're a tech enthusiast, a healthcare professional, or a patient advocate, this conversation offers insights on building smarter, more empathetic digital health solutions. Contact Our Host Steven Newmark, Chief of Policy at GHLF: snewmark@ghlf.org A podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF. We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.org Listen to all episodes of The Health Advocates on our website (https://ghlf.org/the-health-advocates) or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Why We Keep Showing Up TogetherEvery month, Jen and I hop on a call to trade notes, swap links, and compare what's resonating. It's become a favorite ritual because it lets us zoom out and make sense of a very fast month—what we published, what we learned, and where our communities are headed next. We're aligned on mission and complementary in approach: we both want to help people use money for good—while being as rigorous about real-world impact as we are about financials. That's why we keep encouraging readers to subscribe to both publications; you see more of the picture that way.This month, our conversation kept circling around a handful of pieces that sparked big reactions across our communities:* Superpowers for Good: SuperCrowd25: A Movement on the Rise* Superpowers for Good: Power Up October* Main Street Journal: Scamming Social Change* Main Street Journal: Plant DePIN Stations for Fun and Profit* Main Street Journal: Housing Cooperatives & the Better AbundanceWe also name-checked two thinkers whose work regularly sharpens the discussion: Michael Shuman and Paul Spinrad.Authenticity, Impact, and What Changes When You Meet the FounderA thread we returned to repeatedly is the gap between pitch-deck promises and the reality you can feel when you look a founder in the eye—even if it's through a webcam. Jen pointed to how hearing a human, unscripted explanation can dispel both confusion and “impact-washing” skepticism. I see that dynamic every quarter in our Live Pitch sessions: judges arrive with carefully formed opinions and then, after Q&A with founders, their scores often shift—sometimes dramatically. That post-conversation “re-rating” speaks to the power of authentic engagement for investors and founders alike.Michael Shuman's “Scamming Social Change” gave us a crisp lens for that authenticity test. His basic argument: be wary of grand claims about fixing systemic problems with thin mechanisms. He challenged the marketing logic of some “impact” narratives that simply don't add up when you trace how the benefits would actually reach people. For impact investors, the takeaway is simple: scrutinize the causal chain, not just the press release.Three Housing Ideas Worth Stealing (and Scaling)Housing kept bubbling up as a cross-community priority—because you can't talk about poverty, health, or mobility without talking about where people live.* Small, Local, ManyMichael's “Better Abundance” essay argues that big problems don't always demand singular, big solutions; sometimes “many small things in many places” perform better, especially when they're rooted in community context. Jen loved that framing—and it tracks with what we see across Main Street finance and impact crowdfunding: local teams solving local problems, with models that travel.* Co-ops Change the Market, Not Just the Tenant's RentJen highlighted Burlington's Champlain Housing Trust—managing roughly 3,000 affordable homes—as an example of how cooperative models can reset price expectations across a region by forcing the broader market to compete with a fairer baseline. She also flagged a Swiss city where a notable share of residents lives in nonprofit housing—and pointed to eye-poppingly low homelessness figures. The point isn't that co-ops alone “solve” homelessness; it's that a portfolio of modest, durable interventions can shift the whole system.* ADUs as a Practical On-RampCloser to home, Jen's local planning commission in Keene ran an ADU Challenge: homeowners volunteered real sites and constraints; architects and students designed tailored, buildable options; and a $5,000 prize helped surface practical patterns. Policy may permit ADUs on paper, but many would-be “home creators” still need a nudge through the how-to. That kind of lightweight, civic R&D is a smart way to turn latent permission into actual housing.We also touched on work from SuperCrowd25 showcasing rehab-first approaches and manufactured housing as naturally occurring affordable housing (NOAH)—permanent, dignified units that are too often conflated with RVs. In markets where down payments are out of reach, adding safe, lower-cost rentals is an immediate win—and investors can help expand that supply now, not “someday.”A Curious Frontier: Plant DePINOn the more experimental end, Paul Spinrad's “Plant DePIN Stations for Fun and Profit” lit up our curiosity. I'm intrigued by the blend of community incentive design, real-world infrastructure, and open participation. We didn't try to answer every technical or tokenomic question in our chat; we simply acknowledged an emerging space where Main Street builders might find new tools—if (and only if) the impact logic pencils out. As always: first prove the benefit, then scale the mechanism.Movement Notes: SuperCrowd25 & Building the On-RampsIf you missed it, SuperCrowd25 felt like a turning point—less a one-off event and more a widening lane for founders and investors who want returns and results. Our “Movement on the Rise” piece captured why: the people doing the work are getting better at telling the story, and the people funding the work are getting better at asking the right questions. When those two curves meet—clearer storytelling and sharper diligence—capital flows to what actually helps. That's the movement.And because better on-ramps matter, we'll keep making space where founders can show up as themselves and investors can interrogate the “how,” not just the “what.” The more we normalize that practice—the short, human conversation where a founder's logic is audible—the fewer “scamming social change” narratives will slip through undetected.A Candid Ask: Power Up OctoberI also shared something personal with Jen: after 13 years of building this community—rebranding as Superpowers for Good four years ago and launching SuperCrowd two years back—we're close to covering our costs, but not quite there. That's the reason behind our Power Up October campaign. Much of our work remains free by design; paying members make that possible and receive meaningful perks in return (with even more for Max-Impact members). If you've found value in the shows, posts, or pitch sessions, this month is a great time to upgrade or sponsor.Jen shared how the Main Street Journal sustains itself—often through NC3 partnerships and tax-deductible support—and she pledged to help amplify our effort. That kind of mutual aid between aligned media shops is how indie ecosystems survive.Two Subscriptions, One MissionIf you read one of us, you'll get good work. If you read both, you'll get a fuller map—and, frankly, it's still an affordable bundle for a year of actionable ideas. However you support us—subscribe, upgrade, sponsor, or simply share a favorite piece—thank you. We'll keep earning it by elevating founders who solve real problems and by asking the impact questions that make everyone better.—DevinP.S. If you're discovering this via the Main Street Journal, welcome! Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

In this episode, I spoke with Dan Wang, author of “Breakneck: China's Quest to Engineer the Future”, shortlisted for the FT & Schroders Business Book of the Year.Dan is one of the most astute observers of China's technological and industrial development, and his annual letters from Beijing have long been required reading for those seeking to understand the country's evolving role in the world.We unpacked a bold thesis: China is not merely a competitor in AI and tech, but is re-imagining its entire state apparatus as an engineering state - in contrast to the more “lawyerly” institutions of the US and UK.If you're interested in AI, energy or geopolitics, this conversation is for you.We covered: (00:47) Why China is an engineering state(03:40) China's pro-engineering disposition(06:08) The role of market competition in China(08:07) Living through Zero COVID(11:35) What political science terms get wrong(12:58) Characteristics of a lawyerly society(15:23) What Americans misunderstand about China(21:54) Has China produced essential tech?(23:50) The AI divide: China vs. US(27:45) Differences in energy production(32:07) The inherent value of process knowledge(38:34) Is the US developing pro-engineering policies?(44:23) What does it take for countries to compete?Where to find me:Substack: https://www.exponentialview.co/Website: https://www.azeemazhar.com/LinkedIn: https://www.linkedin.com/in/azharTwitter/X: https://x.com/azeemWhere to find Dan:Website: https://danwang.co/LinkedIn: https://www.linkedin.com/in/danwang15/Twitter/X: https://x.com/danwwangProduction by supermix.io and EPIIPLUS1 Ltd, including Chantal Smith, Marija Gavrilov, Nathan Warren and Hannah Petrovic. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

9.30.2025 #RolandMartinUnfiltered: Gov't Shutdown Looms, Jeffries Responds, Hegseth’s Military Policy Shift, GOP PA Rigging ClaimsWe are just hours away from a government shutdown. House Minority Leader Hakeem Jeffries will be here live with the latest on what Democrats are doing to try to stop it.Also, Defense Secretary Pete Hegseth is rolling out big changes to military standards and gender policies. We'll break down what it all means, with analysis from Lt. Col. Davis on the impact for women in uniform.Plus, a Republican PAC is targeting Pennsylvania voters with claims that the state Supreme Court rigged districts for Democrats. We will have a Pennsylvania civic engagement leader join us to set the record straight.And in our Black Star Network Marketplace, we will introduce you to the CEO of 5W Auto, a company revolutionizing car care with eco-friendly, water-saving products.#BlackStarNetwork partner: Fanbasehttps://www.startengine.com/offering/fanbaseThis Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. You should read the Offering Circular (https://bit.ly/3VDPKjD) and Risks (https://bit.ly/3ZQzHl0) related to this offering before investing.Download the Black Star Network app at http://www.blackstarnetwork.com! We're on iOS, AppleTV, Android, AndroidTV, Roku, FireTV, XBox and SamsungTV.The #BlackStarNetwork is a news reporting platform covered under Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research.See omnystudio.com/listener for privacy information.

Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families.   Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u